

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) An isolated nucleic acid molecule comprising a first polynucleotide that comprises a nucleotide sequence chosen from:

(a) ~~SEQ ID NOS.:1-187, 375-484;~~

(b) ~~a polynucleotide encoding a polypeptide comprising [[an]] amino acid sequence SEQ ID NO:215 chosen from SEQ ID NOS.:188-374; or~~

~~(c)(b) a complementary polynucleotide comprising a complementary nucleotide sequence that is complementary to the first nucleotide sequence of (a); and~~

~~(d) a biologically active fragment of any of (a) — (c); and,~~

~~wherein the nucleic acid molecule is an isolated molecule.~~

2. - 4. (Canceled)

5. (Original) The nucleic acid molecule of claim 1, further comprising a second polynucleotide.

6. (Original) The nucleic acid molecule of claim 5, wherein the second polynucleotide comprises a second nucleotide sequence encoding a secretory leader, and the secretory leader is a homologous or heterologous leader.

7. (Canceled)

8. (Currently Amended) An isolated polypeptide comprising ~~[[a]]~~ first amino acid sequence SEQ ID NO:215~~chosen from:~~

~~(a) SEQ ID NOS.:188-374;~~

~~(b) a sequence encoded by one of SEQ ID NOS.:1-187, 375-484; and~~

~~(c) a biologically active fragment of (a) or (b);~~

~~wherein the polypeptide is an isolated molecule.~~

9. - 12. (Canceled)

13. (Original) The polypeptide of claim 8, further comprising a second amino acid sequence, wherein the second amino acid sequence is a secretory leader, the secretory leader is a homologous leader or a heterologous leader, and the first and second amino acid sequences are operably linked.

14. - 17. (Canceled)

18. (Original) A vector comprising the nucleic acid molecule of claim 1 and a promoter that regulates the expression of the nucleic acid molecule.

19. - 22. (Canceled)

23. (Previously presented) A recombinant host cell comprising a cell and the nucleic acid of claim 1.

24. - 29. (Canceled)

30. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a nucleic acid molecule of claim 1.

31. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a polypeptide of claim 8.

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the vector of claim 18.

33. (Canceled)

34. (Previously presented) A host cell composition comprising:

- (a) a recombinant host cell of claim 23; and
- (b) a pharmaceutically acceptable carrier.

35. (Withdrawn; Currently Amended) A method of producing [[a]] the recombinant host cell of claim 23 comprising:

- (a) providing a vector comprising ~~the nucleic acid molecule of claim 1~~ an isolated nucleic acid molecule comprising a first polynucleotide that comprises a nucleotide sequence chosen from:
  - (i) a polynucleotide encoding a polypeptide comprising amino acid sequence SEQ ID NO:215; or
  - (ii) a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of (i); and
- (b) allowing a cell to come into contact with the vector to form a recombinant host cell transfected with the nucleic acid molecule.

36. (Withdrawn; Currently Amended) A method of producing ~~[[a]]~~ the polypeptide of claim 8 comprising:

- (a) providing ~~the nucleic acid of claim 1~~ an isolated nucleic acid molecule comprising a first polynucleotide that comprises a polynucleotide encoding a polypeptide comprising amino acid sequence SEQ ID NO:215; and
- (b) expressing the nucleic acid molecule in an expression system to produce the polypeptide.

37. - 40. (Canceled)

41. (Original) A polypeptide produced by the method of claim 36.

42. - 80. (Canceled)